Clarius Group LLC purchased a new position in Kite Pharma Inc (NASDAQ:KITE) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,920 shares of the biopharmaceutical company’s stock, valued at approximately $345,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of KITE. Teachers Advisors LLC boosted its position in shares of Kite Pharma by 2.6% in the first quarter. Teachers Advisors LLC now owns 119,749 shares of the biopharmaceutical company’s stock worth $9,399,000 after purchasing an additional 3,014 shares during the period. Legal & General Group Plc boosted its position in shares of Kite Pharma by 8.0% during the first quarter. Legal & General Group Plc now owns 14,578 shares of the biopharmaceutical company’s stock worth $1,145,000 after acquiring an additional 1,080 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Kite Pharma during the first quarter worth $5,198,000. Bank of America Corp DE boosted its position in shares of Kite Pharma by 119.6% during the first quarter. Bank of America Corp DE now owns 46,150 shares of the biopharmaceutical company’s stock worth $3,622,000 after acquiring an additional 25,135 shares during the last quarter. Finally, Bank of Montreal Can boosted its position in shares of Kite Pharma by 17.0% during the second quarter. Bank of Montreal Can now owns 8,898 shares of the biopharmaceutical company’s stock worth $923,000 after acquiring an additional 1,293 shares during the last quarter. Institutional investors and hedge funds own 87.72% of the company’s stock.
A number of brokerages recently weighed in on KITE. Canaccord Genuity set a $120.00 target price on shares of Kite Pharma and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Stifel Nicolaus restated a “hold” rating and set a $74.00 target price on shares of Kite Pharma in a research report on Thursday, August 10th. Jefferies Group LLC restated a “buy” rating and set a $135.00 target price (up previously from $121.00) on shares of Kite Pharma in a research report on Wednesday, August 9th. Vetr lowered shares of Kite Pharma from a “buy” rating to a “hold” rating and set a $116.82 target price for the company. in a research report on Monday, August 7th. Finally, SunTrust Banks, Inc. lowered shares of Kite Pharma from a “buy” rating to a “hold” rating in a research report on Monday, August 28th. Thirteen equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Kite Pharma currently has an average rating of “Hold” and an average target price of $94.68.
TRADEMARK VIOLATION WARNING: “Clarius Group LLC Takes $345,000 Position in Kite Pharma Inc (KITE)” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://ledgergazette.com/2017/11/16/clarius-group-llc-takes-345000-position-in-kite-pharma-inc-kite.html.
In other news, Chairman Arie Belldegrun sold 26,347 shares of the stock in a transaction on Monday, September 25th. The shares were sold at an average price of $179.66, for a total value of $4,733,502.02. Following the sale, the chairman now owns 135,507 shares of the company’s stock, valued at $24,345,187.62. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Paul L. Jenkinson sold 948 shares of the stock in a transaction on Monday, September 25th. The shares were sold at an average price of $179.66, for a total transaction of $170,317.68. The disclosure for this sale can be found here. In the last three months, insiders sold 48,936 shares of company stock worth $8,791,842. Insiders own 14.00% of the company’s stock.
Shares of Kite Pharma Inc (NASDAQ:KITE) traded up $0.20 on Thursday, hitting $179.99. 100 shares of the stock traded hands, compared to its average volume of 1,652,408. Kite Pharma Inc has a 1-year low of $39.82 and a 1-year high of $179.99.
About Kite Pharma
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Want to see what other hedge funds are holding KITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kite Pharma Inc (NASDAQ:KITE).
Receive News & Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.